Advertisement
Advertisement
Opsynvi

Opsynvi

Manufacturer:

Penn Pharmaceutical Services Limited
Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.
Core Prescribing Info
Contents
Macitentan, tadalafil
Indications/Uses
Long-term treatment of pulmonary arterial HTN [PAH, World Health Organization (WHO) group 1] in adult patients of WHO functional class (FC) II-III.
Dosage/Direction for Use
Adult ≥18 yr Maintenance dose: 10/40 mg once daily. Patient who are treatment naïve to any PAH specific therapy or those transitioning from endothelin receptor antagonist (ERA) monotherapy Starting dose: 10/20 mg once daily for 1 wk. Maintenance dose: If tolerated, up titrate to 10/40 mg once daily. Patient transitioning from phosphodiesterase 5 inhibitor (PDE5i) monotherapy or those on therapeutic dose of ERA & PDE5i as separate tab 10/40 mg once daily. Patient who are currently treated w/ macitentan 10 mg & tadalafil 20 mg as separate tab 10/20 mg once daily.
Administration
May be taken with or without food: Swallow whole w/ water, do not chew/divide/crush.
Contraindications
Hypersensitivity. Acute MI w/in the last 90 days. Severe hypotension (<90/50 mmHg). Patients who are using any form of organic nitrate. Co-administration w/ guanylate cyclase stimulators (eg, riociguat). Patients who have vision loss in 1 eye because of non-arteritic anterior ischemic optic neuropathy. Severe hepatic impairment w/ or w/o cirrhosis (Child-Pugh class C) or clinically significant elevated hepatic aminotransferases >3x ULN. Women who are or may become pregnant. Lactation.
MIMS Class
Other Antihypertensives
ATC Classification
C02KX54 - macitentan and tadalafil ; Belongs to the class of other antihypertensives. Used in the treatment of pulmonary arterial hypertension.
Presentation/Packing
Form
Opsynvi FC tab 10/20 mg
Packing/Price
1's
Form
Opsynvi FC tab 10/40 mg
Packing/Price
1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement